Sibutramine should be excluded from use in obese patients with preexisting cardiovascular disease.
نویسنده
چکیده
منابع مشابه
Sibutramine on Cardiovascular Outcome
S ibutramine, a combined norepinephrine and serotonin reuptake inhibitor, is effective in the management of obese patients requiring pharmacotherapy as part of a multimodal approach to weight loss. It improves insulin resistance markers, glucose metabolism, and atherogenic dyslipidemia in both diabetic and nondiabetic patients, most of these effects resulting fromweight loss. However, sibutrami...
متن کاملEffect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
BACKGROUND The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. METHODS We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular cons...
متن کاملThe SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients
Moderate weight loss improves metabolic and cardiovascular risk factors and prevents the progression to Type 2 diabetes. Furthermore, a healthy lifestyle is associated with lower cardiovascular mortality, whereas sustained weight loss and increased fitness are both associated with reduced cardiovascular mortality. Currently available antiobesity drugs have been shown to deliver moderate weight ...
متن کاملNew antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Besides genetic predisposition, obesity is the most important risk factor for the development of type 2 diabetes mellitus. Even modest weight reduction can improve blood glucose control in overweight subjects. After failure of lifestyle modifications, antiobesity drugs such as orlistat, a potent and selective inhibitor of gastric and pancreatic lipases that reduces lipid intestinal absorption, ...
متن کاملComparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
BACKGROUND We assessed and directly compared weight loss effects of sibutramine and orlistat treatment in a group of obese, poorly-controlled type 2 diabetic patients. METHODS This study recruited 34 diabetic subjects [glycohemoglobin (HbA1c) > 8%] with a body mass index of at least 27 kg/m2. A 36-week, three-phase, prospective, randomized, cross-over comparative study was conducted. In phase...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Maedica
دوره 5 3 شماره
صفحات -
تاریخ انتشار 2010